VFA
CRBP icon

Valeo Financial Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Valeo Financial Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3
Closed -$1K – 1701
2020
Q2 		$1K Buy
+3
New +$606 ﹤0.01% 1859

Other funds holding CRBP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Valeo Financial Advisors's CRBP Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 3 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in CRBP in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

  • Valeo Financial Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 3 Corbus Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Valeo Financial Advisors first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Valeo Financial Advisors's Corbus Pharmaceuticals position peaked at $1K in Q2 2020.
  • 122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.